ArticleJournal of neuro-oncology2026
Tumor-related epilepsy and preoperative cognitive performance in glioma: a preliminary study.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTumor-related epilepsy (TRE) is also associated with younger age, less aggressive tumor characteristics, and isocitrate dehydrogenase (IDH)-mutant gliomas, all of which may influence cognition. We examined whether preoperative cognitive performance differed according to seizure presentation after accounting for demographic and tumor-related factors.
methodsSixty-five treatment-naïve patients with newly diagnosed glioma were included (TRE, n = 30; non-TRE, n = 35). Neuropsychological performance was expressed as demographically adjusted percentile ranks. Group differences were examined using Mann-Whitney U tests with Benjamini-Hochberg false discovery rate correction. Multivariable regression examined whether the association between seizure presentation and cognition persisted after adjustment for age and enhancing tumor volume. Sensitivity analyses additionally incorporated IDH status and other demographic and clinicopathological variables.
resultsPatients with TRE were younger more educated, had smaller enhancing tumor volumes, lower-grade tumors, and more frequent IDH mutations. Although several cognitive measures favored the TRE group, only Trail Making Test Part A remained significant after correction (median percentile, 83 vs. 21; q = 0.04; r = .41). In multivariable analysis, seizure presentation remained significantly associated with better TMT-A performance after adjustment for age and enhancing tumor volume (B = 0.276, p = .017). The association remained significant in the sensitivity model incorporating IDH status and additional clinicopathological characteristics.
conclusionSeizure presentation was associated with better preoperative TMT-A performance after adjustment for selected demographic and tumor-burden factors. The persistence of this association across sensitivity analyses suggests that TRE may capture clinically relevant aspects of the tumor-brain context that are not fully reflected by conventional demographic, pathological, and molecular characteristics.
Indexed as
Identifiers
42855597What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.